Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2021 | The exosome landscape: quantification and reproducibility is key

Sai-Kiang Lim • 3 Jun 2021

Sai-Kiang Lim, PhD, BA, A*STAR and National University of Singapore, Singapore, provides an overview of the current landscape of exosome-based therapy. Dr Lim notes that while data obtained thus far suggests exosome therapies are efficacious, the key challenge is understanding why and how they work. She highlights the importance of understanding the complexity of the exosome preparation and the need for robust manufacturing protocols to ensure reproducibility. While a number of clinical trials have already been initiated evaluating exosome-based therapies, Dr Lim anticipates that the number of trials will increase in the coming year. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.


Sai-Kiang Lim holds founder shares in Paracrine Therapeutics and is a scientific advisor to ExocoBio and Ilias.